WuXi Biologics (Cayman) PEG Ratio

WuXi Biologics (Cayman)'s peg ratio stands at 1203.87. That is above the Healthcare sector average of 11.77. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

WuXi Biologics (Cayman) sits higher the Healthcare benchmark (11.77) with a PEG ratio of 1203.87. That is roughly 10126.4% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 1203.87 is attractive depends on WuXi Biologics (Cayman)'s earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how WuXi Biologics (Cayman)'s PEG ratio evolved across reporting periods, while the comparison chart places WXIBF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. WuXi Biologics (Cayman)'s reading of 1203.87 (sector avg 11.77) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.